Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

The deal helps move BioNTech’s proposed acquisition of CureVac closer to completion. With the settlement, GSK said it will tender the CureVac shares it owns in support of the $1.25 billion acquisition ...

The tussle had centred on the development of mRNA jab technology, which was at the forefront of the fight against Covid-19.

The Emeryville, California-based biotech has just released topline results from a phase 1/2 head-to-head study comparing its ...

Pfizer plans to sell its 32% stake in Haleon, its consumer health venture with British drugmaker GSK , after the business lists as an independent company in July, GSK said on Wednesday.

GSK (GSK), which is headquartered in Britain, will own just over two-thirds of the joint venture, with US-based Pfizer (PFE) holding the rest.

Pfizer is the most direct challenger to GSK. Like GSK, Pfizer is running a phase 3 trial of a maternal RSV vaccine that is close to delivering data.

For years, the businesses had been a sure and steady income stream for the pharmaceutical giants. Combined, Pfizer and GSK's consumer-health businesses made about $13 billion in sales in 2017.

GSK Plc and Pfizer Inc. are on pace to sell a combined $2 billion of their new RSV vaccines for older adults this year, more than five times what analysts had expected, according to Bloomberg ...

GSK also divulged in the letter that some of its employees heard from the scientist “in late 2020, the three most senior people in Pfizer R&D were involved in a decision to deliberately slow ...